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ABSTRACT
Aim: Long non-coding RNAs (lncRNAs) have been identified to regulate cancers by controlling the process
of autophagy and by mediating the post-transcriptional and transcriptional regulation of autophagy-related
genes. This study aimed to investigate the potential prognostic role of autophagy-associated lncRNAs in
colorectal cancer (CRC) patients. Methods: LncRNA expression profiles and the corresponding clinical
information of CRC patients were collected from The Cancer Genome Atlas (TCGA) database. Based on
the TCGA dataset, autophagy-related lncRNAs were identified by Pearson correlation test. Univariate Cox
regression analysis and the least absolute shrinkage and selection operator analysis (LASSO) Cox regression
model were performed to construct the prognostic gene signature. Gene set enrichment analysis (GSEA)
was used to further clarify the underlying molecular mechanisms. Results: We obtained 210 autophagy-
related genes from the whole dataset and found 1187 lncRNAs that were correlated with the autophagy-
related genes. Using Univariate and LASSO Cox regression analyses, eight lncRNAs were screened to
establish an eight-lncRNA signature, based on which patients were divided into the low-risk and high-risk
group. Patients’ overall survival was found to be significantly worse in the high-risk group compared to that
in the low-risk group (log-rank p 5 2.731E-06). ROC analysis showed that this signature had better
prognostic accuracy than TNM stage, as indicated by the area under the curve. Furthermore, GSEA
demonstrated that this signature was involved in many cancer-related pathways, including TGF-b, p53,
mTOR and WNT signaling pathway. Conclusions: Our study constructed a novel signature from eight
autophagy-related lncRNAs to predict the overall survival of CRC, which could assistant clinicians in
making individualized treatment.
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INTRODUCTION
Colorectal cancer (CRC) is one of the most common gastrointestinal malignant tumors, as well
as the leading cause of death owing to its high morbidity and mortality rates [1]. The global
burden of CRC is expected to increase in developing countries and reach more than 2.2 million
new cases and 1.1 million deaths by 2030 [2]. Although multiple treatments, such as chemo-
therapy, surgery, targeted therapy, radiotherapy, and immunotherapy, have been shown to
reduce relapse and improve the survival of CRC patients, the overall five-year survival rate for
patients suffering from advanced CRC remains very poor [1, 3]. Unexpectedly, patients diag-
nosed with early-stage CRC with an early operation (early surgery) still have a 20–30% recur-
rence rate and are likely to progress into a higher histological grade of malignancy [4]. To date,
patient prognosis still heavily relies on the American Joint Committee on Cancer (AJCC) TNM
staging system. However, it is still a challenge to predict the survival of patients with CRC by
using the current prognostic system because of the wide variability of outcomes and genetic
heterogeneity among patients [5–7]. Thus, identifying reliable prognostic biomarkers to pro-
mote our understanding of cancer development and better predict the overall survival and
prognosis of CRC is greatly desirable.
Autophagy, a protein degradation system, is a critical and highly conserved regulatory
process for cells to maintain function normally by lysosomal degradation of unnecessary or
damaged components [8]. It is a system that runs at basal level in all cells, but the rate of
autophagy increases during times of inflammation, hypoxia, stress, or low nutrition to provide
an additional energy source for the cell [9]. Paradoxically, although autophagy principally plays
an adaptive role to protect cells against various pathologies, the process of autophagy can also
promote carcinogenesis by facilitating the survival of tumor cells under pathological microen-
vironmental stress conditions [10]. Of note, growing evidence has demonstrated the important
role of autophagy in the progression process of CRC [11]. Data from Niklaus et al. indicated that
intact activated autophagy is correlated with a poor prognosis in colon cancer [12]. The auto-
phagy gene Atg4B has been confirmed as an oncogene that facilitates tumor proliferation and a
negative regulator of autophagy in CRC cells [13]. Recently, some studies have tried to find new
effective targeted treatments by studying the function of autophagy [14–16]. For instance,
niclosamide, a new drug for treating metastatic CRC, has been confirmed to inhibit WNT/b-
catenin signaling in CRC cells by degrading components of the pathway via autophagy [17].
Further study of autophagy and its prevalence in patients with CRC will uncover its potential
therapeutic use.
With the development of sequencing technology, the transcriptomes of many organisms
have been surveyed, and these studies identified thousands of transcripts longer than 200
nucleotides in length that do not have significant protein-coding abilities and are thus
termed long non-coding RNA (lncRNA) [18]. A growing amount of evidence has shown that
lncRNAs regulate most cancers by controlling the process of autophagy and by modulating
the post-transcriptional and transcriptional regulation of autophagy-related genes [19, 20].
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For CRC, abnormal expression of several lncRNAs has been proven to be markedly corre-
lated with unfavorable prognosis. According to a recent study, increased levels of POU3F3, a
long intergenic non-coding RNA, were associated with an increased risk of CRC and could
promote metastasis of the neoplasm. Knockdown of POU3F3 was associated with autophagy
induction in CRC cells through BMP signaling, resulting in excessive apoptosis and reduced
invasion and migration capacities of CRC cells [20]. Zheng et al. demonstrated that
increased HAGLROS levels were significantly associated with decreased survival times in
patients with CRC and that downregulated expression of HAGLROS inhibited autophagy in
CRC cells by sponging miR-100 to target and regulate the expression of autophagy gene
Atg5 [21]. Therefore, abnormal expression of autophagy-related lncRNAs may have prog-
nostic value in patients with CRC and could be exploited as a potential molecular target for
cancer therapy.
Currently, gene-based prognostic signatures that incorporate other clinical parameters to
predict overall survival of CRC patients have been thoroughly investigated, but no prognostic
model of CRC based on autophagy-related lncRNAs has been developed. Constructing a pre-
dictive autophagy-related lncRNA signature may be a valuable strategy for predicting the
prognosis of CRC patients. Thus, the objective of this study was to generate an autophagy-




All the Fragments per Kilobase Million (FPKM) normalized expression profile data and the
corresponding clinical information for CRC patients were downloaded and collected from The
Cancer Genome Atlas (TCGA) database, including 647 tumor tissues and 51 non-tumor tissues
(dated to March 18, 2020, https://portal.gdc.cancer.gov/repository). TCGA database is freely
available to the public, thus there was no requirement for additional ethical approval. Based on
the requirement for data integration, we only included CRC patients whose records contained
complete information on clinicopathological variables, including age, gender, tumor stage,
survival status and survival time and those having a survival time of more than 30 days
(implying a probable death caused by CRC). Hence, we included 505 CRC patients for further
analysis.
LncRNA profile mining
The RNA expression data of mRNAs and lncRNAs were obtained from the TCGA dataset
and the expression profiles of mRNAs were normalized by using log2 transformation.
LncRNAs were identified as protein-coding genes or non-coding genes based on their
Ensembl IDs, and only the long non-coding genes in NetAffx Annotation files were retained.
Next, we obtained a latest list of autophagy-related genes by accessing the Human Auto-
phagy Database (HADb, http://autophagy.lu/clustering/index.html). The correlation be-
tween the lncRNAs and autophagy-related genes was conducted by measuring Pearson
correlation coefficients. Autophagy-related lncRNAs were identified with a threshold value
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of P < 0.05 and correlation coefficient |R2| > 0.3. The 505 CRC patients were then randomly
assigned to the training set (50%) and the testing set (50%) (as shown in Supplementary
Table S1). Then we used the training set to construct the prognostic autophagy-related
lncRNAs signature.
Construction and confirmation of an autophagy-related lncRNA signature
To investigate the role of survival-associated lncRNAs as predictive and prognosis
markers in CRC patients, univariate Cox proportional hazards regression was performed
to evaluate the associations between the expression of autophagy-related lncRNAs and
the patients’ overall survival by using the survival R package. Only those lncRNAs of the
test set with a P value less than 0.01 were selected for stepwise model selection by least
absolute shrinkage and selection operator (LASSO) regression analysis, which was further
performed to reduce the variable numbers and effectively avoid overfitting. The LASSO
method was utilized by the package “glmnet” in the R (version 3.6.1) software. Subse-
quently, we constructed a prognostic predictive model using a multivariate Cox hazard
model analysis and calculated the individualized risk score using the following formula:
risk score 5
P
bi3 expRNAi, where expRNA indicates the expression level of a lncRNA
and b is the regression coefficient for the corresponding lncRNA obtained from the
LASSO regression model.
The testing set and the whole set were used to validate the robustness and prognostic value of
this signature. According to the lncRNA-based risk score formula, patients from the training
and testing groups were classified into high-risk and low-risk cohorts using the median risk
score as the cutoff value. Kaplan-Meier curves and log-rank tests were utilized to compare the
two groups’ survival event. Receiver operating characteristic (ROC) analysis was performed to
evaluate the robustness of the prognostic signature for overall survival by calculating the area
under curve (AUC) in the R package of “survival ROC”.
Independent prognostic role of the lncRNA signature
In order to determine whether the prognostic value of the lncRNA signature was independent of
other clinicopathological parameters including age, gender, stage, and TNM status, univariate
and multivariate analyses were performed to measure statistical significance. P < 0.05 was
considered statistically significant.
Gene set enrichment analysis
Gene set enrichment analysis (GSEA, http://software.broadinstitute.org/gsea/index.jsp) is a
powerful computational algorithm based on the JAVA8 platform. In order to identify the
enriched terms and uncover the potential mechanisms underlying the prognostic lncRNAs
signature in our study, Kyoto Encyclopedia of Genes and Genomes (KEGG) functional
enrichment analyses were performed by using the level of risk score as phenotype in GSEA
software. Genes were ranked with the metric of absolute “signal-to-noise” value, and 1000
random sample permutations were carried out. Only KEGG pathways with nominal P values
<0.05, false discovery rates (FDR) <25% and normalized enrichment scores (NES) >1 were
considered to be statistically significant [22].
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Statistical analysis
The autophagy-lncRNA interaction network was analyzed and visualized using Cytoscape
software (version 3.7.2; The Cytoscape Consortium, San Diego, CA, USA). Statistical analyses
were performed using R software (version 3.6.1; The R Foundation for Statistical Computing,
Vienna, Austria). All GSEA analyses presented in our study were performed using a java
implementation of GSEA software (version 4.0.3). A P-value of less than 0.05 was considered to
be statistically significant unless otherwise mentioned.
RESULTS
Construction of autophagy-lncRNAs coexpression networks
A total of 14,142 lncRNAs were obtained from the whole dataset, and the expression profiles
were identified from the microarray dataset by lncRNA expression profile mining. A total of 210
autophagy-related genes were identified from the Human Autophagy Database. A coexpression
network for autophagy-related genes and lncRNAs was constructed and used to find autophagy-
related lncRNAs with a threshold of |R2|>0.3 and P <0.05. Finally, we selected 1,187 autophagy-
related lncRNAs for further analysis. The correlations between the lncRNAs and the autophagy-
related genes are presented in Supplementary Table S2.
Identification of an eight-lncRNA signature in patients with CRC
To extract autophagy-related lncRNAs that actively participated in the onset and progression
of CRC, all autophagy-related lncRNAs in the training dataset were subjected to univariate
Cox proportional hazard regression analysis, and a total of 27 survival-associated lncRNAs
were input into LASSO regression (P < 0.01, Fig. 1A). Then, 19 key lncRNAs were selected for
multivariate Cox regression analysis (Fig. 1B), and eight lncRNAs (AC027307.2, MIR210HG,
FAM160A1-DT, FGD5-AS1, AC023157.3, CD27-AS1, LINC01063, AC145098.1) were further
selected. We further evaluated the autophagy-lncRNA coexpression networks based on the
eight genes (Supplementary Fig. S1). Multivariate Cox hazard model analysis of the associ-
ation of these eight autophagy-related lncRNAs with overall survival showed that two
lncRNAs were independent factors associated with good overall survival in CRC patients
(FAM160A1-DT, FGD5-AS1), whereas six lncRNAs were identified to be unfavorable
prognostic factors for CRC (AC027307.2, MIR210HG, AC023157.3, CD27-AS1, LINC01063,
AC145098.1). The detailed results from the multivariate Cox regression analysis are presented
in Table 1.
Establishment and estimation of the eight-lncRNA prognostic signature
Based on the LASSO regression model, the coefficient values were extracted and a predictive
model containing eight lncRNAs was generated to calculate the risk score of every patient with
the following formula: Risk score 5 expression level of AC027307.2p0.227 þ MIR210HGp0.140
þ FAM160A1-DTp (0.573) þ FGD5-AS1p (0.045) þ AC023157.3p0.484 þ CD27-AS1p0.090
þ LINC01063p0.674 þ AC145098.1p0.485. With the median prognostic score of the training
dataset, 0.857 as the cutoff point, the CRC patients were classified into the low-risk group and
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Fig. 1. Univariate Cox regression and LASSO analysis for screening prognostic features.
(A) The forest plot of 27 survival-associated lncRNAs screened out by univariate Cox proportional hazards
regression. (B) The partial likelihood deviance plot presented the minimum number, which corresponds to
the covariates used for multivariate Cox analysis. LASSO, least absolute shrinkage and selection operator;
lncRNAs: long non-coding RNAs
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the high-risk group; consequently, a prognostic signature based on eight autophagy-related
lncRNAs was developed.
The distribution of the risk score along with the survival status of CRC patients and the
heatmap of the eight autophagy-related lncRNAs in the training dataset were plotted and
are shown in Fig. 2A (a–c), which demonstrates that patients with low risk scores had a
lower death rate and a longer overall survival time than those with high risk scores.
Consistent with this result, the Kaplan-Meier survival curves of the low-risk and high-risk
groups in the training dataset were significantly different, showing overall survival of
33.70% (95%CI 5 19.10%–59.30%) and 86.80% (95%CI 5 77.90%–96.70%) at five years for
patients with high and low risk scores, respectively (log-rank p 5 2.731E-06, Fig. 2A (d)). In
addition, the prognostic power of the eight-lncRNA signature in the training group was
evaluated by calculating the AUC of the ROC curve. ROC analysis showed that the
signature (AUC 5 0.817) had better prognostic accuracy than TNM staging (AUC 5 0.710,
Fig. 2A (e)).
Performance validation of the eight-lncRNA prognostic signature
To confirm the survival prediction power of the signature, we used the testing set (n 5 252)
and the whole set (n 5 505) to assess the findings from the training set. The results are
presented in Fig. 2B and C with risk score analysis, Kaplan-Meier curves and ROC curves.
Consistent with the above findings, the Kaplan-Meier analysis of the two sets showed that the
high-risk group had shorter overall survival time than the low-risk group (log-rank p 5
5.578E-04 in the testing set and log-rank p 5 3.07E-08 in the whole set). The five-year
survival rate was 47.50% (95%CI 5 37.40–60.30%) for patients with high risk scores and
86.20% (95%CI 5 79.60–93.40%) for patients with low risk scores in the whole set. In
addition, the AUCs were 0.698 and 0.762 for testing set and whole set, respectively, indicating
the improved performance of the eight-lncRNA signature model in predicting CRC patient
survival risk.
To further explore the predictive value of the eight-lncRNA signature, Cox regression an-
alyses were utilized based on clinicopathological parameters, including age, gender, and TNM
stage (Fig. 3). Univariate and multivariate Cox regression analysis indicated that age, AJCC T
Table 1. Detailed information for 8 autophagy-related lncRNAs significantly associated with overall
survival in CRC
LncRNA Ensemble ID Coefficient HR HR.95L HR.95H P-value
AC027307.2 ENSG00000267317 0.227 1.255 1.126 1.400 4.24E-05
MIR210HG ENSG00000282810 0.140 1.151 1.039 1.274 0.007
FAM160A1-DT ENSG00000251611 0.573 0.564 0.321 0.991 0.047
FGD5-AS1 ENSG00000225733 0.045 0.956 0.921 0.992 0.018
AC023157.3 ENSG00000276900 0.484 1.623 1.132 2.328 0.008
CD27-AS1 ENSG00000215039 0.090 1.094 1.002 1.195 0.046
LINC01063 ENSG00000232065 0.674 1.961 1.402 2.744 8.39E-05
AC145098.1 ENSG00000248996 0.485 1.624 1.0390 2.540 0.033
Abbreviations: lncRNAs: long non-coding RNAs; HR: hazard ratio; CI: confidence interval.
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Fig. 2. Risk score analysis, Kaplan–Meier survival curves and ROC curves for the autophagy-related
lncRNA signature in CRC.
(A) The distributions of the risk score (a), survival status (b) and expression profiles (c), Kaplan–Meier
curve (d) and ROC curve (e) of the eight-lncRNA prognostic signature in the training set of TCGA cohort.
(B) The distributions of the risk score (a), survival status (b) and expression profiles (c), Kaplan–Meier
curve (d) and ROC curve (e) of the eight-lncRNA prognostic signature in the testing set of TCGA cohort.
(C) The distributions of the risk score (a), survival status (b) and expression profiles (c), Kaplan–Meier
curve (d) and ROC curve (e) of the eight-lncRNA prognostic signature in the whole set of TCGA cohort.
CRC: colorectal cancer; lncRNAs: long non-coding RNAs; ROC: receiver operating characteristic; TCGA:
The Cancer Genome Atlas
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stage, and risk score calculated from the eight-lncRNA signature were independent prognostic
factors for overall survival.
Clinical value of the lncRNA signature in CRC patients
Subsequently, we also determined the clinical value of the eight-lncRNA signature regarding age,
gender, TNM stage, history of colon polyps, tumor status and so on. As presented in Table 2, the
risk score was higher in distant metastasis cases, indicating that the lncRNA signature might be
correlated with the migration and progression of CRC. However, no difference in risk score was
observed according to gender, age, body mass index, history of colon polyps, AJCC stage or with
regards to K-ras status, or mismatch repair status.
Fig. 3. Identifying the independent prognostic parameters in the whole dataset.
(A) The prognostic effect analyses of the autophagy-related lncRNAs signature and commonly used
prognostic factors using univariate Cox regression model. (B) The independent prognostic effect analyses
of the autophagy-related lncRNAs signature and commonly used prognostic factors using multivariate Cox
regression model. lncRNAs: long non-coding RNAs
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Gene set enrichment analysis
To elucidate the underlying biological mechanism of the eight prognostic lncRNAs, we con-
ducted GSEA of the two groups based on the lncRNA signature to find the enriched KEGG
pathways. The results of enriched analysis for the expressed genes in the high-risk group
demonstrated that they were notably enriched in tumor-related and autophagy-related path-
ways. A total of 47 gene sets were significantly enriched with nominal P value <0.05, FDR <25%
and NES >1 in the high-risk group (Supplementary Table S3). The top 10 KEGG pathways are
shown in Fig. 4A. Some of them are involved in the function of autophagy such as peroxisome
and regulation of autophagy. In addition, it was noted that several pathways were involved in the
development and progression of CRC, including pathways in cancer, and the TGF-b, p53,
mTOR and WNT signaling pathways (Fig. 4B). The high-risk group also exhibited enrichment
of one gene signature associated with colorectal cancer. Taken together, the functional
enrichment analysis revealed the potential roles of the prognostic lncRNAs and autophagy in the
carcinogenesis of CRC.




Age (year) ≤65 225 1.731 2.897 1.948 0.052
>65 280 2.338 4.093
Gender Female 233 2.298 4.21 1.297 0.195
Male 272 1.869 3.016
Body mass index (Kg/M2) <25 84 1.691 2.099 0.020 0.984
≥25 163 1.697 2.449
History of colon polyps YES 149 1.466 1.826 0.618 0.537
NO 316 1.361 1.426
AJCC Stage I-II 285 1.808 3.236 1.784 0.075
III-IV 220 2.403 4.045
T stage T1-2 108 1.568 2.774 1.937 0.054
T3-4 397 2.203 3.808
M stage M0 424 1.812 2.943 2.385 0.019
M1 81 3.406 5.877
N stage N0 294 1.788 3.193 1.971 0.05
N1-3 211 2.456 4.116
Tumor status YES 80 2.92 5.901 1.976 0.051
NO 309 1.583 2.666
Radiotherapy YES 27 2.066 3.292 0.208 0.836
NO 407 1.928 3.768
K-ras Wildtype 27 1.866 1.906 0.851 0.399
Mutation 25 1.493 1.205
Loss of expression of mismatch repair
proteins
YES 46 1.145 1.162 1.524 0.132
NO 370 1.437 1.666
Abbreviations: TCGA: The Cancer Genome Atlas; AJCC: American Joint committee on Cancer.
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Fig. 4. Gene set enrichment analysis results based on the signature of eight autophagy-related lncRNAs.
(A) Top 10 of enriched KEGG pathways in the high-risk group. (B) Gene set enrichment analysis indicated
significant enrichment of KEGG cancer-related pathways in the high-risk group. lncRNAs: long non-
coding RNAs; KEGG: Kyoto encyclopedia of genes and genomes; NES: normalized enrichment score
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DISCUSSION
Although extensive research efforts have been made to identify the diagnostic and prognostic
indicators of CRC in the past few decades, there is still a long way to go in constructing good
prognostic tools to predict the survival of CRC patients. Taking advantage of high-throughput
genome sequencing technologies, a group of non-coding RNAs, lncRNAs, have been recognized
and identified. An increased number of studies have shown that aberrantly expressed lncRNAs
are involved in CRC progression and might be novel biomarkers for early detection, prognosis
evaluation and potential targeted treatment of CRC. Moreover, sufficient evidence has shown
that lncRNAs mediate post-transcriptional and transcriptional regulation of autophagy genes to
modulate the complex regulatory network of autophagy [20]. Thus, the study of the prognostic
value of autophagy-related lncRNAs in patients with CRC is of great strategic significance.
In the present study, to help clarify the prognostic potential of autophagy-related lncRNAs in
CRC, we found 1187 lncRNAs through the coexpression network of lncRNAs and autophagy-
related genes using a large cohort from TCGA. Next, we used univariate and LASSO Cox
regression analyses to identify the lncRNAs significantly correlated with the overall survival of
patients with CRC and establish a prognostic eight-lncRNA signature. Further, the prognostic
signature categorized CRC patients into low-risk and high-risk groups with significantly
different survival outcomes, which was validated by the ROC analysis and Kaplan-Meier overall
survival curve. This signature showed great consistency and performance throughout the testing
set and whole set. Further univariate and multivariate Cox regression analyses indicated that the
signature possessed an independent prognostic ability, indicating that it can predict the survival
of CRC patients independently. In addition, we explored the underlying molecular mechanisms
by using GSEA between subgroups. These results implied that the eight-lncRNA signature might
serve a crucial role in the pathomechanism of CRC and could be used as a new biomarker to aid
prediction of prognosis in patients with CRC.
There were eight lncRNAs in the prognostic signature and all of them had been annotated by
using Ensembl database, but little is known about their biological roles in cancer progression
and tumorigenesis. In our study, we found that FGD5-AS1 was an independent factor associated
with good overall survival in CRC patients. FGD5-AS1 has been reported as an oncogene in
non-small-cell lung cancer and oral squamous cell carcinoma, as its aberrant expression and
dysregulation can promote tumorigenesis [23, 24]. Li et al. demonstrated that high-level
expression of FGD5-AS1 was found in CRC cell lines, which suppressed apoptosis, accelerated
proliferation and helped CRC cells to spread through negatively regulating miR-302e [25]. To
date, no study has focused on the expression of FGD5-AS1 in the CRC tissue. The paradoxical
results of our study may be due to the type of experiment used in the previous study, therefore
further clinical trials are warranted to delineate the role of FGD5-AS1 in patients suffering from
CRC. MIR210HG was found to have a positive correlation with risk score (regression coefficient
5 0.140), which demonstrated that higher MIR210HG expression was associated with poorer
CRC prognosis. Consistent with our studies, MIR210HG has been found to be overexpressed in
lung cancer [26], osteosarcoma [27], invasive breast cancer [28], and hepatocellular carcinoma
[29], and its overexpression predicts a poor prognosis and a lower overall survival rate. A recent
study revealed that MIR210HG may exert its effects in colon cancer through the modulation of
energy metabolism and cell adhesion, but experimental evidence should be provided in future
studies [30]. CD27-AS1 has been reported to be downregulated in cervical carcinoma [31].
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However, studies on CD27-AS1 in cancer are, so far, limited in number. In addition, there
weren’t any reports on the other five lncRNAs according to a PubMed search. Therefore, further
investigations are needed to clarify the functions of these lncRNAs in CRC and other cancers.
In recent years, remarkable advances in genomic techniques have enabled rapid identifica-
tion of an increasing number of genomic alterations involved in the occurrence, development
and progression of CRC, such as common mutations, chromosomal changes and translocations
[32]. Multiple genomic aberrations have been reported to influence critical functions within the
cell (p53 and cell-cycle regulation) and vital pathways (TGF-b, WNT and MAPK/PI3K) [33]. In
the present study, KEGG pathway analysis indicated that the functions of the eight lncRNAs
were potentially correlated with the TGF-b, p53, mTOR and WNT signaling pathways. These
results reveal that the eight-lncRNA signature contributes to important cancer pathways, which
may add an important piece of evidence for targeted therapy for CRC. Notably, these signaling
pathways are known to regulate autophagy. Among these, mTOR signaling is an important
signaling pathway that acts as a central regulator in the complex process of autophagy and
promotes cancer progression, and mTOR inhibitors have provided therapeutic efficacy toward
CRC [34]. Besides, there is already evidence that p53, a key tumor suppressor gene, can either
stimulate or inhibit autophagy. For example, p53 can directly activate the transcription of a set
of autophagy-relate genes including Atg7 and Ulk1 [35]. In contrast with this study, p53 has
been identified to prevent the activation of autophagy in several cell lines in response to several
distinct stimuli [36]. The two pathways of p53 and autophagy are now functionally linked,
providing new insights into their mechanisms in cancer progression and tumorigenesis. Un-
derstanding the functional interactions between the autophagy process and the p53 pathway
may have some benefit for the treatment of CRC.
To the best of our knowledge, the eight autophagy-related lncRNA signature has not been
previously reported, and showed improved performance compared to the conventional clinical
parameters such as TNM stage, implying a more precise reflection of the substantial hetero-
geneity of CRC. It is anticipated that the signature could be a valuable and useful biological tool
for CRC diagnosis and prognosis. However, this study has limitations. First, all of our samples
and clinical data were based on the TCGA dataset. The prognostic value of the eight-lncRNA
signature should be further validated in cohorts with larger sample sizes from other datasets in
the future. Furthermore, the information on several other important clinicopathological features,
such as adjuvant chemotherapy use, was unavailable in these datasets. Third, the expression of
the eight lncRNAs warrants further investigation in clinical trials. Fourth, based on data ob-
tained from TCGA, we performed a bioinformatics analysis to identify the prognostic auto-
phagy-related lncRNAs, and the functions of the lncRNAs were not characterized using in vitro
or in vivo experimentation. Further studies are required to delineate the role of these lncRNAs in
CRC, measure their effects on cell autophagy and determine the mechanisms involved in the
progression and tumorigenesis of CRC.
Taken together, we identified a signature of eight autophagy-related lncRNAs for predicting
overall survival in CRC patients by analyzing a coexpression network of lncRNAs and autophagy-
related genes. It accurately separates CRC patients with unfavorable prognosis from those with
favorable prognosis, which may assist physicians in formulating more efficient therapeutic strate-
gies. The present study not only shows the value of an eight autophagy-related lncRNAs signature
as a promising classification tool for CRC diagnosis and prognosis but also potentially opens a new
field in the role and regulation of autophagy in the tumorigenesis and progression of CRC.
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